Category: St. Jude Medical
Here's a look at some of the top regulatory stories for medical device companies this week: Shareholder files class action lawsuit to block Covidien-Medtronic merger; St. Jude drops $200M on NeuroTherm for spinal pain device; Allergan renews fight against hostile Valeant takeover; Abbott to deal pharma line to Mylan for $5.3B
St. Jude Medical's 2nd-quarter results, including a 2% gain for its implantable cardiac defibrillator business, could signal a rebound for the ICD sector overall, according to Leerink Partners.
St. Jude Medical enters the spinal pain treatment arena with the $200 million cash acquisition of NeuroTherm and its radiofrequency ablation technology.
Minnesota-based medtech giant St. Jude Medical (NYSE:STJ) is broaching new ground in the spinal pain market with the $200 million acquisition of NeuroTherm, maker of radiofrequency ablation therapies.
Here's a look at some of the top regulatory stories for medical device companies this week: FDA aims to stay the course in new 4-year plan; Medical device recalls for June 2014; Medtronic issues Class I recall of Duet neuro drainage and monitoring systems; FDA warns Staar Surgical for missing documentation; FDA clears St. Jude Medical after 2013 warning letter
MassDevice.com speaks to 3M's Deb Rectenwald, St. Jude Medical's Philip Ebeling and Nadim Yared, CEO of CVRx, about the environment for M&A in medtech following the $43 billion Medtronic/Covidien deal.
A federal judge rules that most of the product liability claims against St. Jude Medical are preempted in a trio of lawsuits filed over its recalled Riata defibrillator leads.